Zoetis appoints Mark Stetter to board; Robert Scully retires

Zoetis Inc.

Robert Scully retired from Zoetis board effective May 21, 2025, under director retirement policy.
Mark Stetter elected to board at annual meeting; received 371.2M votes for, 0.4M against.
Shareholders approved executive compensation (334.2M for, 35.2M against) and ratified KPMG as auditor (384.8M for, 7.6M against).
Shareholder proposal to improve special meeting process failed with 50.4M for vs. 320.7M against.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Stetter

director

ZTS · Zoetis Inc.

Effective: 2025-05-21
Filed: May 22, 2025, 7:59 PM ET

Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.

Departed

Robert Scully

director

ZTS · Zoetis Inc.

Effective: 2025-05-21
Filed: May 22, 2025, 7:59 PM ET

Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Stetter was elected as director at Zoetis Inc..

Action: elected
Role: director

Exact text from the filing

Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Scully retired as director at Zoetis Inc..

Action: retired
Role: director

Exact text from the filing

Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc.

View on SEC.gov

Zoetis Inc. filing history →

Source: SEC EDGAR

accession 0001555280-25-000213

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.